The maintenance of an Overweight rating suggests that JP Morgan still sees HealthEquity as a good investment. However, the reduction in the price target could imply that there are some concerns or headwinds that might limit the stock's upside potential in the short term. This news is highly relevant to HealthEquity as it directly affects investor perception and could lead to a neutral short-term impact on the stock price as the market digests the new price target.